Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cellscreen Of Australia Plans To Take HPV Test Global

This article was originally published in PharmAsia News

Executive Summary

Australia's Cellscreen Direct plans to market its Tam-Pap test for the human papilloma virus in a global market it deems to be worth $4 billion. The home test for HPV was approved by the Therapeutics Goods Administration last year to join a vaccine and the pap smear test on the Australian market. Cellscreen said that by raising the funds to go global, it expected to raise the current 60 percent rate for screening, attracting some of the many women uncomfortable with the pap smear. The Australian firm already has applied with the U.S. FDA and expects to seek EU approval early next year. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts